Pro Forma Financial Information The Company acquired Avient Protective Materials (“Dyneema”) on September 1, 2022 (the “Acquisition Date”) and sold the Distribution segment on November 1, 2022. To provide comparable results, the company references “pro forma” financial metrics, which include the business results of Avient Protective Materials for periods prior to the Acquisition Date, as if the transaction occurred on January 1, 2021 and reflect Distribution as a discontinued operation. Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years. 28 EV / 2023E EBITDA Historic Multiple 6.5 8.3 9.5 13.8 12.7 12.6 11.3 8.7 18.6 16.5 10.1 10.0 9.7 9.5 9.4 8.7 01 1) 01 8) 02 3) Avient Specialty Other Specialty / SEGMENT DATA U.S. & Canada 40% 37% 18% 2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Building and END MARKET REVENUE $2,355M $402M $1,300M $272M Sales EBITDA Specialty Engineered Materials Color Additives and Inks $592M$3,653M (1) 9% 30 (1) Total company sales and adjusted EBITDA of $3,653M and $592M, respectively, include intercompany sales eliminations and corporate costs 2022 REVENUE | $2 .4 B ILL ION 34% 38% END MARKET REGION 31 34% 21% Building & 1% Energy 2% COLOR, ADDITIVES & INKS 2022 PRO FORMA REVENUE | $1 .3 B ILL ION 52% 35% 32 19% 8%Industrial 16% 9% Defense Building & END MARKET REGION SPECIALTY ENGINEERED MATERIALS 32% 27% 14% Building & 3% 1% Defense 1% (18% of sales) 9% 2022 PROFORMA AVIENT REGIONAL SALES 27% 14% 17% Building & (37% of sales)Transportation 12% Building & US & Canada (40% of sales) 7% 56% 23% 7% Building & 1% LATAM (5% of sales) 3% 33 BY END MARKET Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

Avient acquired the Clariant Masterbatch business (CMB) on July 1, 2020 (the “Acquisition Date”). Reduce Scope 1 & 2 greenhouse gas emissions by 35%. Operating Income $3,783 $4,100 (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition Previous Guidance Current Guidance $3,783 $4,300 $308 $360 $308 $410 $1.93 $2.40 $1.93 $2.80 (1) (1)(1) (1)(1) (1) $442 $457 $560 $1.74 $1.93 $2.80 FULL YEAR 2019 – 2021 ORGANIC GROWTH 23 Sales Adjusted EBITDA $3,981 $3,783 $4,300 + 8% (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition (1)(1) + 27% + 61% 24 BALANCE SHEET • Deleveraging to 1.9x net debt to adjusted EBITDA by the end of 2021 • Driven by record adjusted EBITDA performance and strong free cash flow generation from asset light business • Future cash deployment: M&A, opportunistic share repurchases and balance sheet / continued leverage reduction 3.5x 2.7x 1.9x Net Debt / Adjusted EBITDA ($ in millions) 2021E Adjusted EBITDA 560$ Free Cash Flow 275$ Total Debt 1,860 Less: Cash (800) Net Debt 1,060$ 2021E Net Debt / Adjusted EBITDA 1.9x (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition PEER COMPARISONS 25 As a specialty formulator, we don’t require significant capital investment, as compared to the base resin raw material suppliers we purchase from.

Geon(TM) DB5261 Neutral TT Iso Stable Shipment Notification - under "Material Header" MSDS - labeled as the "Product Number" (in Section 1)

This statement has been published in accordance with section 54(1) of the Modern Slavery Act 2015 and constitutes the second modern slavery and human trafficking statement of ColorMatrix Europe Limited (“ColorMatrix”) and covers the 2024 financial year. Global ISO Certificate Library

WIRE &CABLE COMPANY O P T I C A L C A B L E S H E A T H • Excellent resistance to fungi and mildew • Good UV resistance • Meet flame retardant standard IEC 60332-3C • Provided an anti-fungi solution with an ISO 846 rating of 0, showing no growth under microscope • Formulated solution to meet flammability performance demands for IEC60332-2 or GBT 18380.22-2008 compliance • Complied with Biocidal Product Regulation (EU) No528/2012 (BPR) ECCOH™ Thermoplastic Formulation KEY REQUIREMENTS WHY AVIENT?

Versaflex - CPAP tubing film CPAP TUBING C O R R U G A T E D T U B I N G F I L M • Replacement for polyolefins • Good spring-back • Bondable cuffs • Clear & clean look • Minimize humidity and condensation within the tube • No noticeable odor • FDA, ISO 10993 & USP VI compatible • Provided TPE solution to meet market expectations for improved user comfort & aesthetics • Reduced tube noise and improved drape compliance with new material solution versus polyolefins • Offered solution with improved thermal properties to combat humidity Versaflex™ CL2250 KEY REQUIREMENTS WHY AVIENT?

A LIFE SCIENCE COMPANY S E R U M C O L L E C T I O N C A R T R I D G E • Excellent clarity • Good bonding and peel strength onto PP • Heat resistance • Meet sterilization needs • Easy processing • Formulated transparent Shore 50A TPE with excellent adhesion onto PP and good sealing performance • Met regulatory requirements for USP Class VI and ISO 10993-4,5 • Provided a short lead time and on-site technical service Versaflex™ CL Thermoplastic Elastomers KEY REQUIREMENTS WHY AVIENT?

PRE-FILLED SYRINGE COMPANY S Y R I N G E T I P C A P • Excellent sealing performance • No DEHP or natural rubber latex added during processing • Can be sterilized by EtO • Compliant with ISO 10993-4&5 and USP Class VI • Formulated a solution that met rigorous medical application requirements • Leveraged global footprint to ensure supply continuity • Increased process efficiency by replacing previous thermoset material with a TPE Versaflex™ HC Thermoplastic Elastomers KEY REQUIREMENTS WHY AVIENT?

ORTHOPEDIC PARTS MANUFACTURER O R T H O P E D I C S O L E I N S E R T • A super soft TPE (

Avient acquired the Clariant Color business on July 1, 2020 (the “Acquisition Date”). Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $580M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) 86 93 85 83 79 77 75 89 85 83 81 79 79 78 77 74 en t (10) Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below many of our specialty formulator peers. With the Clariant Color business acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 33 Avient reflects 2021 estimated EBITDA of $580M OUR VALUATION VERSUS PEERS Avient Specialty Other 11.4 20.2 16.7 16.5 14.7 12.0 10.8 40.7 29.9 26.2 13.2 12.4 11.0 10.9 9.1 9.0 7.5 6.5 en t SUMMARY: WHY INVEST IN AVIENT?